Boston Scientific Co. (NYSE:BSX) Shares Sold by iSAM Funds UK Ltd

iSAM Funds UK Ltd decreased its position in Boston Scientific Co. (NYSE:BSX - Free Report) by 84.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,493 shares of the medical equipment provider's stock after selling 18,473 shares during the quarter. iSAM Funds UK Ltd's holdings in Boston Scientific were worth $312,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BSX. TFC Financial Management Inc. grew its stake in shares of Boston Scientific by 308.8% in the fourth quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 210 shares in the last quarter. Colonial Trust Co SC grew its stake in shares of Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 260 shares in the last quarter. Valley National Advisers Inc. grew its stake in shares of Boston Scientific by 262.4% in the fourth quarter. Valley National Advisers Inc. now owns 395 shares of the medical equipment provider's stock worth $35,000 after acquiring an additional 286 shares in the last quarter. Fairway Wealth LLC acquired a new position in shares of Boston Scientific in the fourth quarter worth $36,000. Finally, Global Trust Asset Management LLC grew its stake in shares of Boston Scientific by 64.5% in the fourth quarter. Global Trust Asset Management LLC now owns 436 shares of the medical equipment provider's stock worth $39,000 after acquiring an additional 171 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $106.52 on Wednesday. The company has a 50-day simple moving average of $99.61 and a 200-day simple moving average of $96.97. Boston Scientific Co. has a one year low of $71.88 and a one year high of $107.17. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The stock has a market capitalization of $157.59 billion, a price-to-earnings ratio of 85.22, a PEG ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business had revenue of $4.66 billion during the quarter, compared to analysts' expectations of $4.57 billion. During the same period in the prior year, the company earned $0.56 earnings per share. The business's revenue was up 20.9% compared to the same quarter last year. On average, analysts predict that Boston Scientific Co. will post 2.85 EPS for the current year.

Insider Buying and Selling

In related news, EVP John Bradley Sorenson sold 4,572 shares of the stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $104.54, for a total transaction of $477,956.88. Following the completion of the transaction, the executive vice president now directly owns 18,705 shares of the company's stock, valued at $1,955,420.70. This represents a 19.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $104.25, for a total transaction of $487,368.75. Following the transaction, the executive vice president now directly owns 28,454 shares of the company's stock, valued at $2,966,329.50. This represents a 14.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 195,830 shares of company stock valued at $20,043,415 over the last ninety days. Corporate insiders own 0.50% of the company's stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of several research reports. BTIG Research restated a "buy" rating and issued a $124.00 price target on shares of Boston Scientific in a research note on Wednesday, April 23rd. Stifel Nicolaus boosted their target price on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a research note on Thursday, February 6th. Evercore ISI boosted their target price on shares of Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. Needham & Company LLC boosted their target price on shares of Boston Scientific from $113.00 to $115.00 and gave the stock a "buy" rating in a research note on Thursday, April 24th. Finally, Morgan Stanley boosted their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a research note on Friday, May 16th. Twenty-three analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Boston Scientific has an average rating of "Buy" and an average price target of $114.74.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.